PDCD1 and neoplasm: Similarly to other studies our work also demonstrated that more than 10% of PD-L1 negative patients received also benefit by anti PD-1/ PD-L1 therapies, suggesting that tumor PD-L1 expression could not be able to predict the overall immunotherapy benefit in NSCLC [32, 33].